BRPI0921651A2 - Método para produzir adenovírus recombinante, e partículas virais, e, biorreator - Google Patents

Método para produzir adenovírus recombinante, e partículas virais, e, biorreator

Info

Publication number
BRPI0921651A2
BRPI0921651A2 BRPI0921651-0A BRPI0921651A BRPI0921651A2 BR PI0921651 A2 BRPI0921651 A2 BR PI0921651A2 BR PI0921651 A BRPI0921651 A BR PI0921651A BR PI0921651 A2 BRPI0921651 A2 BR PI0921651A2
Authority
BR
Brazil
Prior art keywords
bioreactor
viral particles
recombinant adenovirus
producing recombinant
producing
Prior art date
Application number
BRPI0921651-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfred Luitjens
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BRPI0921651A2 publication Critical patent/BRPI0921651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BRPI0921651-0A 2008-11-03 2009-10-29 Método para produzir adenovírus recombinante, e partículas virais, e, biorreator BRPI0921651A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (1)

Publication Number Publication Date
BRPI0921651A2 true BRPI0921651A2 (pt) 2015-08-18

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921651-0A BRPI0921651A2 (pt) 2008-11-03 2009-10-29 Método para produzir adenovírus recombinante, e partículas virais, e, biorreator

Country Status (15)

Country Link
US (1) US10041049B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350268B1 (cg-RX-API-DMAC7.html)
JP (1) JP5770633B2 (cg-RX-API-DMAC7.html)
KR (1) KR101504392B1 (cg-RX-API-DMAC7.html)
CN (1) CN102203242B (cg-RX-API-DMAC7.html)
AU (1) AU2009319254B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921651A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742474C (cg-RX-API-DMAC7.html)
DK (1) DK2350268T3 (cg-RX-API-DMAC7.html)
EA (1) EA019928B1 (cg-RX-API-DMAC7.html)
ES (1) ES2532015T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011004292A (cg-RX-API-DMAC7.html)
NZ (1) NZ593235A (cg-RX-API-DMAC7.html)
PL (1) PL2350268T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010060719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
CN102791852B (zh) * 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
KR101820980B1 (ko) * 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA023614B1 (ru) 2011-02-10 2016-06-30 Круселл Холланд Б.В. Пневматическая безмембранная система разделения клеток с переменным давлением
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
CN105473712B (zh) * 2013-08-30 2022-05-27 葛兰素史密丝克莱恩生物有限公司 在细胞培养物中大规模生产病毒
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
HK1252967A1 (zh) 2015-08-20 2019-06-06 Janssen Vaccines & Prevention B.V. 治疗性hpv18疫苗
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
WO2017180724A1 (en) * 2016-04-12 2017-10-19 Artemis Biosystems, Inc. Perfusion filtration systems
BR112018072372A2 (pt) 2016-05-02 2019-02-19 Janssen Vaccines & Prevention B.V. combinações de vacina terapêutica contra o hpv
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
US11142551B2 (en) 2017-10-31 2021-10-12 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
EP3704256A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CN111372943B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
CA3079210A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
KR20250111232A (ko) 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
EP3784276A4 (en) 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CA3144960A1 (en) * 2019-07-01 2021-01-07 Ology Bioservices, Inc. Method for cultivation of adherent cells in a multiparallel bioreactor
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
EP4314019A2 (en) 2021-04-01 2024-02-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4590689A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
AU2023355822A1 (en) 2022-10-06 2025-04-17 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
WO1999041416A2 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EA200001096A1 (ru) 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040043489A1 (en) 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
KR100762033B1 (ko) 1998-12-31 2007-10-04 아방티 파르마 소시에테 아노님 바이러스 입자의 분리방법
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
DK1550722T3 (da) 1999-05-17 2007-10-08 Crucell Holland Bv Rekombinant human adenovirus serotype 35
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
JP4488290B2 (ja) 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート 効率的ターゲティングのためのファイバーシャフト変異
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
BR0308783A (pt) 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
WO2003097797A2 (en) 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
JP2007525166A (ja) 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子
HRP20130616T1 (en) 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
EP1720972B1 (en) * 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US7629167B2 (en) 2004-06-04 2009-12-08 Xcellerex, Inc. Disposable bioreactor systems and methods
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
MX2007004031A (es) 2004-10-14 2007-11-08 Crucell Holland Bv Vacunas de cebado/refuerzo contra el paludismo.
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
WO2006086284A2 (en) 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
JP2008541730A (ja) 2005-05-23 2008-11-27 ヴァクシン インコーポレイテッド 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法
US20100115874A1 (en) 2005-07-22 2010-05-13 Pergo (Europe) Ab Flooring system including a dry glue
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
AU2007276217B2 (en) 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
CA2705260C (en) 2007-11-14 2013-08-06 Chun-Chieh Chang Method and devices for producing air sensitive electrode materials for lithium ion battery applications
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
MA33429B1 (fr) 2009-07-16 2012-07-03 Crucell Holland Bv Production de poliovirus à titres élevés pour la production de vaccins
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS

Also Published As

Publication number Publication date
ES2532015T3 (es) 2015-03-23
EP2350268A1 (en) 2011-08-03
MX2011004292A (es) 2011-05-31
HK1160664A1 (en) 2012-08-10
CN102203242B (zh) 2013-06-12
KR20110093793A (ko) 2011-08-18
CA2742474C (en) 2016-05-31
WO2010060719A1 (en) 2010-06-03
DK2350268T3 (en) 2015-03-23
US10041049B2 (en) 2018-08-07
PL2350268T3 (pl) 2015-05-29
CN102203242A (zh) 2011-09-28
JP2012507270A (ja) 2012-03-29
JP5770633B2 (ja) 2015-08-26
KR101504392B1 (ko) 2015-03-19
EA201170638A1 (ru) 2011-12-30
US20110207202A1 (en) 2011-08-25
EP2350268B1 (en) 2014-12-24
AU2009319254B2 (en) 2015-04-30
EA019928B1 (ru) 2014-07-30
AU2009319254A1 (en) 2010-06-03
NZ593235A (en) 2013-02-22
CA2742474A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
BRPI0921651A2 (pt) Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
LTPA2018015I1 (lt) Genų inžinerijos būdu pagaminti anti-IL-23P19 antikūnai
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0919575A2 (pt) método, e, composição
BRPI0914145A2 (pt) métodos para produzir polimerização por radical controlada, e para obter distribuição por radical atva controlada.
BRPI0919199A2 (pt) suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas
BR112012005424A2 (pt) método para produzir n-propanol, e, microorganismo
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BR112012000296A2 (pt) composição e método para produção de um propante cerâmico ultraleve.
BR112013010725A2 (pt) método, e, composição
BRPI0823277A2 (pt) Composição, e , método
BRPI0917714A2 (pt) método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada
BR112012002657A2 (pt) composição polimerizável para material ótico, material ótico e processo para produção de material ótico
BR112012002137A2 (pt) método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição
GB0822068D0 (en) Methods for virus design
BRPI0921106A2 (pt) biocombustível e processo para preparação de biocombustível
BRPI0921438A2 (pt) Hospedeiros e processos de fermentação para produção de celulase
BRPI1014516A2 (pt) Biorreator de estado sólido, estático, e método para usar o mesmo
BRPI0921380A2 (pt) processo para preparar partículas oxidantes, e, partículas oxidantes de tamanho reduzido
GB201213167D0 (en) Compositions,methods and related uses for cleaving modified DNA
BRPI1006996A2 (pt) composição, método e uso
BRPI0823238A2 (pt) Composição, e, método
BRPI0918633A2 (pt) método para calcinar matérias-primas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.